TSLP Receptor Monoclonal Antibody (eBio1A6 (1A6)), eBioscience™, Invitrogen™

Description

• The eBio1A6 MAb reacts with human thymic stromal-derived lymphopoietin receptor (TSLPR)
• TSLPR is an approximately 50 kDa protein with significant similarity to the common gamma-chain
• TSLPR complexes with IL-7R alpha (CD127) to form the high affinity receptor that binds thymic stromal-derived lymphopoietin (TSLP)
• Human TSLPR is expressed by monocytes and CD11c+ dendritic cells, and TSLP binding induces the expression of the Th2 cell-attracting chemokines CCL17 and CCL22
• Furthermore, the TSLPR-induced activation of dendritic cells indirectly results in the increased secretion of Th cytokines IL-4, -5 and -13, which may be necessary for the regulation of CD4+ T cell homeostasis
• In mice, deficiency of TSLPR has no effect on lymphocyte numbers, whereas double deficiency of TSLPR and common gamma-chain results in fewer lymphocytes than seen in mice deficient in the common gamma-chain alone
• The eBio1A6 MAb is able to cross-block binding of another anti-human TSLPR MAb, 1D8
• Thymic stromal lymphopoietin (TSLP) has recently been identified as an important factor capable of driving dendritic cell maturation and activation
• It is involved in the positive selection of regulatory T cells, maintenance of peripheral CD4+ T cell homeostasis and the induction of CD4+ T cell-mediated allergic reaction
• TSLP is also capable of supporting the growth of fetal liver and adult B cell progenitors and their differentiation to the IgM-positive stage of B cell development
• Its receptor TSLP-R will bind TSLP in a low-affinity fashion in transfected cells; co-transfection with IL-7R-alpha cDNA results in high-affinity binding and a functional heteromeric complex
• This heteromeric receptor requires stat5 for TSLP-mediated signal transduction and is inhibited by SOCS-1.